Dr Reddys Laboratories Ltd (RDY) Cotización

RDY new 52 week high

RDY new 52 week high

Dr. Reddy's recent acquisition of MenoLabs marks a strategic move into the fast-growing women’s nutritional and wellness markets. Here's why this is a smart play for their growth outlook:

Expanding Product Portfolio: With MenoLabs' seven branded products, Dr. Reddy's is not just acquiring assets but diversifying into a niche yet increasingly significant market of menopause and perimenopause health support. This expansion can attract a new customer base and meet unaddressed needs.

Leveraging E-commerce: MenoLabs' products have a strong presence in e-commerce platforms like Amazon and Walmart. This aligns with the growing trend of online healthcare shopping, potentially increasing reach and sales with minimal physical infrastructure investment.

Innovative Health Tracking: The acquisition includes the MenoLife health tracker app, which is more than just a product; it's an engagement tool. By offering a community and educational resources, Dr. Reddy's can foster brand loyalty and gather valuable consumer insights for future development.

Tapping into a Growing Market: Women's health, particularly around menopause, is an underrepresented field with significant growth potential. As the global population ages, the demand for these specialized healthcare solutions will likely increase, positioning Dr. Reddy's ahead in the market.

Overall, this acquisition seems to be a well-calculated move to not only diversify Dr. Reddy's offerings but also to capitalize on a growing market with innovative products and platforms. It's a step toward becoming a more consumer-centric healthcare company with a strong foothold in the women's wellness segment.

https://www.thehindubusinessline.com/news/dr-reddys-buys-menolabs-business/article67701634.ece

Breaking News: $RDY Dr. Reddy's Laboratories Announces the Launch of Dimethyl Fumarate Delayed-Release Capsules in the U.S. Market

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr.Reddy’s”) today announced the launch of Dimethyl Fumarate Delayed-Release Capsules, a therapeutic equivalent generic version of Tecfid...

In case you are interested RDY - Dr. Reddy's Laboratories Announces the Launch of Dimethyl Fumarate Delayed-Release Capsules in the U.S. Market

News: $RDY Dr. Reddy's Laboratories Announces Acquisition of ANDA Portfolio

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced today that it has entered into a definitive agreement to acquire a portfolio of 42 approved, non-marketed Abbreviated ...

Got this from https://marketwirenews.com/news-releases/dr-reddy-s-laboratories-announces-acquisition-of-anda-portfolio-7995468.html

$RDY http://thewellesleysnews.com/2017/09/19/stocks-that-may-be-worth-big-bets-dr-reddys-laboratories-limited-rdy-westwater-resources-inc-wwr/

Good thing nobody here is looking.
We sank 17% today!...sigh

$RDY DD Notes ~ http://www.ddnotesmaker.com/RDY

bullish

$RDY recent news/filings

## source: finance.yahoo.com

Mon, 24 Nov 2014 07:29:00 GMT ~ Dr. Reddy’s Announces the Launch of Docetaxel Injection USP

[Business Wire] - HYDERABAD, India--(BUSINESSWIRE)-- Dr. Reddy’s Laboratories (NYSE: RDY) announced today that is has launched Docetaxel Injection USP 20 mg/mL and 80 mg/4 mL a therapeutic equivalent generic version of ...

read full: http://au.finance.yahoo.com/news/dr-reddy-announces-launch-docetaxel-072900029.html
*********************************************************

Mon, 24 Nov 2014 07:29:00 GMT ~ Dr. Reddy’s Announces the Launch of Docetaxel Injection USP

[Business Wire] - Dr. Reddy’s Laboratories announced today that is has launched Docetaxel Injection USP 20 mg/mL and 80 mg/4 mL a therapeutic equivalent generic version of TAXOTERE® in the US market on November 21, 2014.

read full: http://finance.yahoo.com/news/dr-reddy-announces-launch-docetaxel-072900058.html
*********************************************************

Thu, 20 Nov 2014 23:03:13 GMT ~ Consumer Retail/Spending top the Lg Cap List...


read full: http://finance.yahoo.com/tumblr/blog-consumer-retail-spending-top-the-lg-cap-list-230315654.html
*********************************************************

Thu, 20 Nov 2014 14:15:00 GMT ~ Dr. Reddy’s Announces the Launch of Over-the-Counter Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets

[Business Wire] - HYDERABAD, India--(BUSINESSWIRE)-- Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched its over-the-counter (OTC) Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended ...

read full: http://au.finance.yahoo.com/news/dr-reddy-announces-launch-over-141500549.html
*********************************************************

Thu, 20 Nov 2014 14:15:00 GMT ~ Dr. Reddy’s Announces the Launch of Over-the-Counter Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets

[Business Wire] - Dr. Reddy’s Laboratories announced today that it has launched its over-the-counter Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets 60 mg / 120 mg, a bioequivalent generic version of Allegra-D® 12 Hour Allergy & Congestion, in the U.S.

read full: http://finance.yahoo.com/news/dr-reddy-announces-launch-over-141500492.html
*********************************************************


$RDY charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$RDY company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/RDY/company-info
Ticker: $RDY
OTC Market Place: Not Available
CIK code: 0001135951
Company name: Dr. Reddy's Laboratories Ltd.
Company website: http://www.drreddys.com
Incorporated In: India


$RDY share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
$RDY extra dd links

Company name: Dr. Reddy's Laboratories Ltd.
Company website: http://www.drreddys.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/RDY/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/RDY/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=RDY+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=RDY+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=RDY+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/RDY/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/RDY/news - http://finance.yahoo.com/q/h?s=RDY+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/RDY/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/RDY/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/RDY/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/RDY/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/RDY/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/RDY/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/RDY/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/RDY/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=RDY+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/RDY
DTCC (dtcc.com): http://search2.dtcc.com/?q=Dr.+Reddy%27s+Laboratories+Ltd.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Dr.+Reddy%27s+Laboratories+Ltd.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Dr.+Reddy%27s+Laboratories+Ltd.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.drreddys.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.drreddys.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.drreddys.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/RDY/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/RDY
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/RDY/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/RDY/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/RDY/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001135951&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/RDY/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/RDY/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/RDY/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/RDY/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=RDY&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=RDY
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/RDY/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=RDY+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=RDY+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=RDY
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=RDY
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=RDY+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/RDY/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=RDY+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/RDY.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=RDY
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/RDY/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/RDY/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/RDY/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/RDY/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/RDY
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/RDY
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/RDY:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=RDY
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=RDY



$RDY DD Notes ~ http://www.ddnotesmaker.com/RDY

Is this stock associated with Dr. M.S. Reddy?

Target price $42 next 6 months

Before market, it raised $1.35, great. This month it will touch $40.

Tomorrow it may up by $ 1.00

Great company! Now signed MOU with Fujifilm to enter for generic business in Japan. Must be rcrossing $50 stock price by jan'12.

Dr Reddy launched 135 new genetic products, filed 107 NDAs and 56 Drug Master Files globally. GREAT MARKET in coming 2 years.

check my posts in Biotech values board

Any one to share their views on RDY?

It's ringfence time at Reddy's
C Chitti Pantulu / DNA MONEY
Wednesday, 07 May , 2008, 09:52


The Orchid Chemicals lesson has not been lost on Dr Reddy's Laboratories.

More India business stories

The Hyderabad-based company's promoters are seeking to ringfence India's second largest pharma player.

Dr Reddy's vice-chairman and chief executive G V Prasad told DNA Money that the company's board, at a meeting on January 25, had approved a preferential issue of share warrants up to 5% of the existing equity of DRL, exercisable into an equal number of equity shares.

"We have not exercised that option because we haven't approached shareholders yet," he said, adding that the option may be looked at now.

The Bombay Stock Exchange's records show that promoters held 25.14% in Dr Reddy's as on March 31, 2008.

Asked about hostile bids, Prasad said the management was hoping to create good shareholder value and through this, keep such threats low.

"The only way (to avoid hostile bids) is to keep the share price from dipping. It shouldn't become low enough to attract such bids," he said.

But Dr Reddy's shares haven't exactly been soaring on the BSE.

The shares fell 8.49% to Rs 643.80 on Tuesday. After touching a high of Rs 747 on January 2, the company's shares have dipped 14% to date. Prasad blames the problems being faced by Betapharm, the German generics maker it acquired in 2006 to the drag on Dr Reddy's. Price reforms introduced by Germany in April have made life difficult.

The other factors that have hurt its performance are increasing rebates to insurance companies and a change in the composition of Betapharm's top products.

More India business stories

Prasad, however, felt that the downswing is temporary and won't hurt the company in the long term.

http://sify.com/finance/fullstory.php?id=14668506

Source: IRIS (05 May 2008)

Dr Reddy`s Laboratories allotted 2,870 equity shares of Rs 5 each of the company on May 03, 2008, to company employees under the Dr. Reddy`s Employees Stock Option Scheme, 2002.

In addition, the compensation committee of the board of directors of the company has allotted 17,604 ADRs of Rs 5 each on May 03, 2008, to the US employees of the company under Dr. Reddy`s Employees ADR Stock Option Scheme, 2007.

Dr. Reddy`s is a vertically integrated, global pharmaceutical company with proven research capabilities and presence across the pharmaceutical value chain. It manufactures active pharmaceutical ingredients (APIs) and finished dosage forms and markets them globally, with a focus on United States, Europe, India and Russia.

Shares of the company gained Rs 6, or 0.95%, to settle at Rs 638.45. The total volume of shares traded was 31,724 at the BSE (Monday).

http://www.myiris.com/newsCentre/newsPopup.php?fileR=20080505180745181&dir=2008/05/05&secID=livenews

Dr. Reddy's Announces the Completion of Two Acquisitions
Thursday May 1, 7:23 am ET

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories (NYSE:RDY - News) announced that it has completed two acquisitions: The Dow Chemical Company’s Dowpharma Small Molecules Business associated with its Mirfield and Cambridge, UK sites and BASF’s pharmaceutical contract manufacturing business and related facility in Shreveport, Louisiana, USA. Further financial terms and conditions of the transaction are not being disclosed.

The acquisition of The Dow Chemical Company’s Dowpharma Small Molecules Business associated with the 2 UK sites includes the relevant business, customer contracts, associated products, process technology, intellectual property, and trademarks as well as the transfer of the Mirfield and Cambridge facilities. Employees directly related to the business located at the Cambridge and Mirfield sites will become part of Dr Reddy’s. Dr. Reddy’s will also have a non-exclusive license to Dow’s Pfēnex Expression Technology™ for biocatalysis development.

The acquisition of BASF’s pharmaceutical contract manufacturing business and related facility includes the relevant business, customer contracts, related ANDAs and NDAs, trademarks, as well as the manufacturing facility and assets at Shreveport, Louisiana. It also includes a tolling and supply agreement. Employees directly related to the business located at Shreveport site will become part of Dr Reddy’s.

Disclaimer

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy’s

Dr. Reddy’s Laboratories was established in 1984 in Hyderabad, India, and is a global pharmaceutical company with proven research capabilities. Dr. Reddy’s conducts research in the areas of diabetes, obesity, cardiovascular diseases, anti-infectives and inflammation. The Indian based company produces finished dosage forms, active pharmaceutical ingredients and biotechnology products which are marketed globally, with focus on India, US, Europe and Russia. (www.drreddys.com)


Contact:

Dr. Reddy's Laboratories
Nikhil Shah, +91-40-66511532
(Investors and Financial Analysts)
nikhilshah@drreddys.com
Mythili Mamidanna, +91-40-66511620 (Media)
mythilim@drreddys.com

Source: Dr. Reddy's Laboratories


http://biz.yahoo.com/bw/080501/20080501005568.html?.v=1

http://www.reuters.com/article/marketsNews/idINDEL3297520080417?rpc=44

NEW DELHI, April 17 (Reuters) - India's leading drug makers
should report rises in quarterly earnings on strong generic
drugs sales, with the exception of Dr Reddy's Laboratories
(REDY.BO: Quote, Profile, Research) whose profit is seen falling sharply due to one-time gains in last year's earnings. Cheaper generic drugs are becoming increasingly popular as
governments around the world battle to contain soaring
healthcare costs, but export-driven Indian pharmaceutical firms
are facing challenges of stiff pricing pressure in the United
States. Analysts are upbeat about the outlook for the sector as
drugs with annual U.S. sales of $50 billion are expected to go
off patent by 2010, creating more opportunities for Indian
firms to sell generic versions or cheap copies of branded
products. "We believe that the worst is over for Indian generic
companies and expect gradual improvement in their performance
over the next two years," Motilal Oswal Securities said in a
report. An increased focus on the domestic market, which is
expected to maintain the 12-14 percent growth rate of recent
years, should help drug makers in the long term, Prabhudas
Lilladher said. Ranbaxy Laboratories (RANB.BO: Quote, Profile, Research), India's top drug maker by sales, is expected to post a 15.5 percent rise in March quarter sales when it reports on Tuesday, but higher interest costs and lower other income mean its profit will rise by just 2.3 percent on year to 1.32 billion rupees, according to a Reuters poll. (See bottom of story for company valuation, share price movement and a table of forecasts) Goldman Sachs, which maintains a strong outlook for the sector in the financial year that began on April 1, estimates
average industry sales growth to be 21 percent from a year
earlier, more than its previous forecast of 16 percent. The Indian rupee weakened by 1.7 percent against the dollar in the March quarter, after rising more than 12 percent in 2007, which could have led to some foreign exchange hedging losses, analysts said. New York-listed Dr Reddy's (RDY.N: Quote, Profile, Research) is expected to report a 64 percent fall in net profit, as earnings a year earlier were boosted by one-time gains from a 180-day exclusivity period for the generic version of GlaxoSmithKline's (GSK.L: Quote, Profile, Research) anti-nausea
drug Zofran. The company also faces pressure on its business in Germany, where it acquired Betapharm for $572 million in 2006. The acquisition has been a drag on earnings because of supply
constraints and the appreciation of the rupee. Sun Pharmaceuticals (SUN.BO: Quote, Profile, Research), India's most valuable drug maker, is expected to report its net profit rose 15 percent to 2.65 billion rupees, buoyed by sales of oxcarbazepine tablets, a generic form of Novartis AG's (NOVN.VX: Quote, Profile, Research) epilepsy drug Trileptal. Sun shares exclusive U.S. marketing rights with Indian peer Glenmark Pharmaceuticals (GLEN.BO: Quote, Profile, Research) for the drug. Cipla Ltd (CIPL.BO: Quote, Profile, Research) is expected to report a 39.4 percent rise in net profit on revenue growth of 9.6 percent, helped by higher exports. Pharmaceutical stocks outperformed the main index in a falling market during the January-March quarter, with the BSE healthcare index falling 13 percent, versus a 23 percent drop in the benchmark index .BSESN.

continued....

Dr. Reddy's Buys Italy Drug Distributor
Thursday April 3, 7:35 am ET
Dr. Reddy's Buys Italian Generics Distributor Jet Generici

NEW YORK (AP) -- Dr. Reddy's Laboratories Ltd., the India-based pharmaceuticals company, said Thursday it bought Italian distributor of generic drugs Jet Generici Srl.

Dr. Reddy's did not disclose financial terms of the deal.

The company hopes to expand its presence in Italy, where it operates Reddy Pharma Italia, SpA.

Dr. Reddy's Enters Into Drug Discovery Collaboration With 7TM Pharma on Selected Drug Targets
Monday March 10, 7:03 am ET

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories (NYSE:RDY - News) and 7TM Pharma announced today the signing of drug discovery collaboration on selected drug targets in the area of metabolic disorders.

Under the terms of the agreement, Dr. Reddy’s and 7TM Pharma will collaborate to identify clinical candidates for pre-selected targets. Both the parties will jointly develop these candidates from the pre-clinical stage up to Phase IIa (proof-of-concept). On successful completion of a Phase IIa study, the companies may either license-out the candidate for further development and commercialization to a larger pharmaceutical company or continue the further co-development and commercialization jointly. The financial terms of the agreement have not been disclosed.

Mette Kirstine Agger, CEO of 7TM Pharma commented: “It is exciting to be working with Dr Reddy’s, as they have developed strong R&D capabilities and combining this with 7TMs expertise in the GPCR area and SD3 (7TM’s technology platform) we are looking forward to a fruitful collaboration.”

Dr. Rajinder Kumar, President of Research, Development and Commercialization, Dr. Reddy’s, commented: “7TM has established a track record as one of the leading Drug Discovery companies focusing on GPCRs, and we are excited at the prospects of combining 7TM’s capabilities with Dr. Reddy’s to discover and develop innovative products.”

Disclaimer

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy’s

Dr. Reddy’s Laboratories was established in 1984 in Hyderabad, India, and is a global pharmaceutical company with proven research capabilities. Dr. Reddy’s conducts research in the areas of diabetes, obesity, cardiovascular diseases, anti-infectives and inflammation. The Indian based company produces finished dosage forms, active pharmaceutical ingredients and biotechnology products which are marketed globally, with focus on India, US, Europe and Russia. (www.drreddys.com)

Dr. Reddy’s Contact Information:

Investors and Financial Analysts:

Nikhil Shah at nikhilshah@drreddys.com or on +91-40-66511532

Media:

Mythili Mamidanna at mythilim@drreddys.com or on +91-40-66511620

About 7TM Pharma

7TM Pharma is a biotech company focusing on discovery and development of new drugs targeting 7TM receptors. 7TM Pharma’s primary therapeutic area is metabolic diseases, including obesity, Type 2 diabetes and cardiovascular diseases.

The basis for 7TM Pharma’s drug discovery is a thorough and comprehensive knowledge about 7TM receptors including their structure, function and pharmacology which the company uses in the design of new potential drugs. In recent years, the company has established a broad pipeline of research and development programs based on in-house drug discovery and development, and entered into several research partnerships, including with Ortho-McNeil Inc. (a subsidiary of Johnson & Johnson).

Since its inception in 2000, 7TM Pharma has raised DKK 610 million (EUR 82 million). Investors include Index Ventures, Novo A/S, Alta Partners, LD Pensions, Johnson & Johnson Development Corporation, Dansk Innovationsinvestering, Sofinnova Capital, Healthcare Private Equity Limited Partnership, Lombard Odier Darier Hentsch & Cie, SR One, Global Life Science Ventures, Baker/Tisch Investments, Credit Agricole Private Equity, GIMV and BioMedinvest AG. For more information on 7TM Pharma, please visit www.7tm.com.

7TM Pharma

Contact person:

Mette Kirstine Agger, CEO

Tel: +45 39 25 77 77

Email: agger@7tm.com

Notes to the Editor:

About 7TM Receptors (GPCRs): 7TM receptors (GPCRs) contain a generic protein structure of 7 bundled transmembrane (7TM) helices that is extensively used for a variety of stimuli e.g. photons, monoamines, fatty acids, peptide hormones, and glycoproteins. Approximately 40% of today’s prescription drugs target 7TM receptors, but utilize only 5% of the known 7TM receptor targets. 7TM Pharma is tightly integrating its structure based drug discovery approach, Site-Directed Drug Discovery®, with traditional medicinal chemistry and expert knowledge on peptides and has thereby created a drug discovery platform that accelerates the generation of new drugs targeting 7TM receptors.


Contact:

Dr. Reddy’s Laboratories
Nikhil Shah, +91-40-66511532 (Investors and
Financial Analysts)
nikhilshah@drreddys.com
Mythili Mamidanna, +91-40-66511620 (Media)
mythilim@drreddys.com
or
7TM Pharma
Mette Kirstine Agger, CEO, +45 39 25 77 77
agger@7tm.com

Source: Dr. Reddy's Laboratories

http://biz.yahoo.com/bw/080310/20080310005633.html?.v=1